{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021239","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.695425+00:00","generated_at":"2026-06-15T04:12:03.739543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Athira Pharma Q1 net loss $27.8M; focuses Alzheimer's trial on 40 mg dose","bullets":["Net loss $27.8M ($0.73/share) vs $21.0M ($0.56) in Q1 2022; cash $219.9M.","Phase 2/3 LIFT-AD trial to focus on 40 mg fosgonimeton; 70 mg arm discontinued.","Open-label extension extended to up to 30 months; >85% enrollment from prior trials.","ATH-1105 preclinical data in ALS shows prolonged survival and improved motor function; IND-enabling work for 2024 first-in-human.","End of Phase 2 meeting with FDA scheduled for summer 2023; timeline update expected."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021239","json":"https://secwatch.observer/filing/0000950170-23-021239.json","markdown":"https://secwatch.observer/filing/0000950170-23-021239.md","text":"https://secwatch.observer/filing/0000950170-23-021239.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/0000950170-23-021239-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/atha-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:12:03.739543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"73054316b9f0c4ca7131d0a79e0a82ce904fd52e","claim":"LeonaBio, Inc. reported financial results for the first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1620463/000095017023021239/0000950170-23-021239-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}